Veracyte, Inc. VCYT
50.41 USD +1.41 (+2.87%)
Nov 3, 2026, 3:31 PM EST
49.88 Day range 51.42
29.46 52-week range 60.91
- YTD
- +19.73%
- 1 year
- +38.29%
- Market cap
- 4.05B
- Revenue (ttm)
- 561.90M
- Profit margin
- 20.37%
- EPS (ttm)
- 1.40
- Shares out
- 80.39M
- P/E ratio
- 36.01
- Forward P/E
- 25.22
- YTD return
- +19.73%
- 1-year return
- +38.29%
- Volume
- 459.39K
- Avg volume
- 1.30M
- Open
- 49.95
- Previous close
- 49.00
- Day's range
- 49.88 – 51.42
- 52-week range
- 29.46 – 60.91
- Beta
- 1.96
- Analysts
- Strong Buy
- Price target
- 59.73 (+18.5%)
- Earnings date
- Nov 4, 2026
5D +0.50 (+1.00%)
Key statistics
- Enterprise value
- 3.58B
- PEG ratio
- 0.00
- Price / sales
- 7.01
- Price / book
- 2.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 15.50%
- Free cash flow
- 106.23M
- Total cash
- 485.23M
- Total debt
- 40.11M
- Return on equity
- 8.77%
- Short % of float
- 14.44%
- 50-day average
- 44.42
- 200-day average
- 42.82
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 59.73 +18.5% upside
Now 50.41
- Target (low)
- 45.00
- Target (mean)
- 59.73
- Target (high)
- 70.00
Ratings (0m) 12 11 buy · 1 hold · 0 sell
- Strong buy2
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.40973.
Financials — quick view
VCYT Revenue — quarterly 150.32M
VCYT Net income — quarterly 25.49M
VCYT EPS — quarterly 0.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.41 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.4103 | 0.54 | +0.13 | +31.61% |
| May 5, 2026 | Mar 31, 2026 | 0.34 | 0.52 | +0.18 | +52.94% |
| Feb 25, 2026 | Dec 31, 2025 | 0.4083 | 0.53 | +0.12 | +29.81% |
| Nov 4, 2025 | Sep 30, 2025 | 0.32 | 0.51 | +0.19 | +59.38% |
| Aug 6, 2025 | Jun 30, 2025 | 0.31 | 0.44 | +0.13 | +41.94% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 15, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Sep 9, 2026 | UBS | main | Buy | Buy |
| Aug 4, 2026 | Piper Sandler | main | Overweight | Overweight |
| Aug 4, 2026 | Stephens & Co. | main | Overweight | Overweight |
| Aug 4, 2026 | Morgan Stanley | main | Underweight | Underweight |
| Aug 3, 2026 | Canaccord Genuity | main | Hold | Hold |
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- veracyte.com
News
Ten Afirma Abstracts to Highlight Thyroid Nodule Diagnosis and Cancer Research at ATA 2026 
Veracyte to Participate in Upcoming Investor Conferences 
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? 
Artisan Mid Cap Fund Q3 2026 Portfolio Update 
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer 
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? 
Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell? 
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 
Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program 
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Your note
Sign in to keep a note on VCYT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARR ELIAV | Director | Stock Award(Grant) | Jun 10, 2026 | 56,461 |
| BHANJI MUNA | Director | Sale | Oct 18, 2026 | 40,854 |
| CHAMBERS REBECCA | Chief Financial Officer | Sale | Sep 3, 2026 | 166,025 |
| EPSTEIN ROBERT S | Director | Stock Award(Grant) | Jun 10, 2026 | 57,718 |
| FEBBO PHILLIP G | Officer | Sale | Sep 3, 2026 | 133,048 |
| HAAS KEVIN RICHARD | Officer | Stock Award(Grant) | Apr 9, 2026 | 44,221 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.78% | 13,486,437 | 660.84M | Jun 29, 2026 |
| FMR, LLC | 9.58% | 7,702,746 | 377.43M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 6.89% | 5,538,404 | 271.38M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.87% | 4,716,191 | 231.09M | Jun 29, 2026 |
| State Street Corporation | 5.84% | 4,698,128 | 230.21M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 3,593,922 | 176.10M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 4,787,107 | 234.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.15% | 2,532,110 | 124.07M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.90% | 2,332,081 | 114.27M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.60% | 2,092,968 | 102.56M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 1,830,642 | 89.70M | Jun 29, 2026 |
| ARK ETF Trust-ARK Innovation ETF | 2.07% | 1,666,407 | 81.65M | Sep 29, 2026 |